Aignostics, a Berlin, Germany-based global AI company specializing in multi-modal pathology data analysis, has raised $34 million in Series B funding, bringing its total funding to over $55 million.
Investors
The oversubscribed round was led by ATHOS, with additional investments from Mayo Clinic and growth financing from HTGF. Existing investors, including Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie (managed by IBB Ventures), also participated.
ATHOS, a single-family office with a strong background in healthcare and life sciences, supports innovative companies that positively impact health and well-being. Known publicly as the long-term majority investor in BioNTech, ATHOS remains dedicated to fostering medical innovation and building transformative companies for the future.
Aignostics Use of Funds
The company will use the funds to enhance product offerings for biopharmaceutical clients, expand operations in the U.S. market, and develop advanced foundation models in collaboration with Mayo Clinic.
About Aignostics
Aignostics is an AI company focused on transforming complex pathology data into actionable insights for precision medicine. Leveraging proprietary clinical data, advanced technology, and scientific rigor, Aignostics supports drug discovery, translational research, clinical trials, and companion diagnostics (CDx) for biopharma partners. Founded in 2018 as a spin-off from Charité, it operates in Berlin and New York.
Funding Details
Company: Aignostics GmbH
Raised: $34.0M
Round: Series B
Funding Date: October 2024
Lead Investor: ATHOS
Additional Investors: Mayo Clinic, HTGF, Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, VC Fonds Technologie
Company Website: https://www.aignostics.com/
Software Category: AI Precision Diagnostics
Source: https://www.prnewswire.com/news-releases/aignostics-secures-34-million-series-b-to-enhance-precision-medicine-with-ai-302288975.html